Johnson & Johnson can’t get $70M Risperdal verdict tossed at Pennsylvania appeals court
Johnson & Johnson has faced numerous negative headlines on its talc and opioid litigation in recent months, but at the same time, lawsuits over its antipsychotic Risperdal present another set of challenges. And lately, they’re not going the company’s way. Despite J&J’s efforts to get a 2016 Risperdal verdict against the drugmaker—worth $ 70 million in actual… Read More »